Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging
Erschienen in: Nuclear Medicine and Molecular Imaging 3/2011

01.09.2011 | Case Report

Assessment of Therapeutic Effect of Sunitinib by 11C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma

verfasst von: Nobuyuki Oyama, Noriko Takahara, Yoko Hasegawa, Kazuya Tanase, Yoshiji Miwa, Hironobu Akino, Hidehiko Okazawa, Takashi Kudo, Yasuhisa Fujibayashi, Osamu Yokoyama

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Although sunitinib shows a high response rate in patients with untreated metastatic renal cell carcinoma (mRCC), quite a few patients show no therapeutic effect. Therefore, it is crucial to distinguish the patients who respond to sunitinib from those who do not as early as possible after the administration of the therapy. We herein report a case of mRCC in which 11C-acetate (AC) positron emission tomography (PET) showed an early therapeutic effect of sunitinib treatment 4 weeks after its administration.
Literatur
1.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24.PubMedCrossRef
2.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRef
3.
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef
4.
Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18 F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–45.PubMedCrossRef
5.
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed
6.
Haberkorn U, Bellemann ME, Brix G, Kamencic H, Morr I, Traut U, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med. 2001;28:418–25.PubMedCrossRef
7.
Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.PubMedCrossRef
8.
Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med. 1995;36:1595–601.PubMed
9.
Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117–22.PubMedCrossRef
10.
Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.PubMedCrossRef
11.
Maleddu AM, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, et al. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009;95:382–4.PubMed
Metadaten
Titel
Assessment of Therapeutic Effect of Sunitinib by 11C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma
verfasst von
Nobuyuki Oyama
Noriko Takahara
Yoko Hasegawa
Kazuya Tanase
Yoshiji Miwa
Hironobu Akino
Hidehiko Okazawa
Takashi Kudo
Yasuhisa Fujibayashi
Osamu Yokoyama
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 3/2011
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-011-0084-x

Weitere Artikel der Ausgabe 3/2011

Nuclear Medicine and Molecular Imaging 3/2011 Zur Ausgabe

Case Report

A Case of Meigs’ Syndrome: The 18F-FDG PET/CT Findings

Original Article

Evaluation of Salivary Gland Dysfunction Using Salivary Gland Scintigraphy in Sjögren’s Syndrome Patients and in Thyroid Cancer Patients after Radioactive Iodine Therapy

Original Article

Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using 18F-FDG PET/CT and 99mTc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation

Interesting Image

F-18 FDG PET/CT of a Gastric Schwannoma

Case Report

Bilateral Tubo-Ovarian Abscess Mimics Ovarian Cancer on MRI and 18F-FDG PET/CT

Original Article

Clinical Significance of Diffuse 18F-FDG Uptake in Residual Thyroid Gland after Unilateral Thyroid Lobectomy